ArticleAdvances in therapy2025
Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.Dermatology and therapy · 2026Article
- Case Report: Abrocitinib treatment for refractory palmoplantar pustulosis.Frontiers in medicine · 2026Article
- Letter to the Editor Regarding "Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study".Advances in therapy · 2025Article
- Response to Letter Regarding: "Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study".Advances in therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPalmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.
methodsA retrospective cohort study, using healthcare claims data from patients aged ≥ 18 years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM
resultsBiologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8-100%]; Optum, 61% [8-99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18-64 versus ≥ 65 years (279 [132] vs 258 [140] days).
conclusionIn patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.